Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by nodaytraderon Jan 20, 2022 10:35am
133 Views
Post# 34337218

RE:RE:RE:RE:RE:RE:RE:Streetwise Reports:

RE:RE:RE:RE:RE:RE:RE:Streetwise Reports:The endangerment of Algernon by price depression, IMO, would be a public harm to honest investors and sick people who would benefit from Algernon's disease remedies.

It is the duty and responsibility of regulators to promote public good, including reducing public harm, by ensuring that the activities they regulate do not result in public harm. That duty would include suggesting changes to existing laws, if appropriate.

it is the duty and responsibility of legislators to make laws to reduce public harm,

I have written to all the regulators and to my MP and the CSE about this. Four parties in total of which one replied . From the other three - nothing, not even an acknowledgment.

the one regulator who did reply claimed it was not their responsibility but did not say that they would refer it on.

so, while the CEO may bear some responsibility, the ultimate responsibility, IMO, lies with regulators and legislators - and they seem to be failing in that duty.


<< Previous
Bullboard Posts
Next >>